Quest Diagnostics Incorporated (NYSE:DGX) : Zacks Investment Research ranks Quest Diagnostics Incorporated (NYSE:DGX) as 3, which is a Hold recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. Not everyone is convinced about the stocks future, hence, the stock receives 1 Sell recommendation. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 13 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 16 research analysts is 3.02, which indicates as a Hold.
Quest Diagnostics Incorporated (NYSE:DGX) : The highest level Quest Diagnostics Incorporated (NYSE:DGX) is projected to reach is $84 for the short term and the lowest estimate is at $70. The consolidated price target from 12 rating analysts who initiate coverage on the stock is $75.42 and the possibility the share price can swing is $3.87.
Company shares have received an average consensus rating of Hold for the current week Also, Brokerage firm Jyske Bank downgrades its rating on Quest Diagnostics Incorporated (NYSE:DGX). The shares have been rated Sell. The rating by the firm was issued on June 24, 2016.
Quest Diagnostics Incorporated (NYSE:DGX): stock turned positive on Tuesday. Though the stock opened at $77.74, the bulls momentum made the stock top out at $78.41 level for the day. The stock recorded a low of $77.5 and closed the trading day at $78.24, in the green by 0.85%. The total traded volume for the day was 1,631,957. The stock had closed at $77.58 in the previous days trading.
In an insider trading activity,The officer (SVP, Clin. Franchise Solutions) of Quest Diagnostics Inc, Doherty Catherine T. sold 47,334 shares at $77.27 on May 27, 2016. The Insider selling transaction had a total value worth of $3,657,498. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business, consists of two parts, develops and delivers diagnostic testing, information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, patients and other customers. Diagnostics Information Services business also provides diagnostic information services, which includes providing clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses, including central laboratory testing for pharmaceutical and medical device clinical trials, risk assessment services, diagnostic products and healthcare information technology.